The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer

Yamaki,Minoru; Shinozaki,Katsunori; Sakaguchi,Takemasa; Meseck,Marcia; Ebert,Oliver; Ohdan,Hideki; Woo,Savio  L.C.

doi:10.3892/ijmm.2012.1205

February 2013 Volume 31 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2013 Volume 31 Issue 2

Full Size Image

Article

The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer

Authors:
- Minoru Yamaki
- Katsunori Shinozaki
- Takemasa Sakaguchi
- Marcia Meseck
- Oliver Ebert
- Hideki Ohdan
- Savio L.C. Woo
View Affiliations / Copyright

Affiliations: Department of Surgery, Division of Frontier Medical Sciences, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan, Department of Virology, Basic Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan, Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA, Second Medical Department, Klinikum Rechts der Isar, Technical University of Munich, Munich D-81675, Germany, Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
Pages: 299-306
|
Published online on: December 6, 2012

https://doi.org/10.3892/ijmm.2012.1205
Expand metrics +

Abstract

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer-related mortality in the United States. The liver and lung are the most common sites of distant metastasis of CRC. The approval of newer chemotherapeutic agents such as oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab has significantly improved survival, yet the majority of patients still succumb to the disease in less than 2 years. Novel therapeutic agents that can provide significant clinical benefit for metastatic CRC patients are needed. Oncolytic vesicular stomatitis virus (VSV) is a promising tool as a cancer therapeutic agent. In this study, we examined the feasibility of repeated intravenous infusions of rVSV in multiple CRC lung metastases, compared with repeated hepatic arterial administration in multifocal CRC liver metastasis in immune competent rats. We established a multifocal liver metastases model or the multiple lung metastases model using a CRC cell line, RCN-H4, implanted into syngeneic F344/DuCrj rats. 4.0x106 plaque-forming units (pfu) of recombinant VSV vectors expressing mutant (L289A) Newcastle disease virus fusion protein [rVSV-NDV/F(L289A)] were administered 3 times for 3 consecutive days locally via the hepatic artery for liver metastases or systemically via the penial vein for lung metastases. In the liver metastasis model, significantly enhanced survival was observed with rVSV-NDV/F(L289A)-treated rats (P=0.0196). Median survival was 110 and 25 days, respectively. In addition, 4 out of 7 of the rVSV-NDV/F(L289A)-treated rats demonstrated long-term survival exceeding 100 days. The long-term surviving rats were sacrificed to evaluate for residual malignancy. Liver tumors were not detected. In the lung metastasis model, median survival was 10 [VSV-NDV/F(L289A)-treated rats] and 7 days (control). Although survival was significantly prolonged (P<0.001), none of the rats achieved long-term survival. VSV virotherapy has potential for CRC liver and lung metastases, although systemic venous delivery is much less effective than locoregional delivery such as hepatic arterial infusion.

View Figures

View References

1.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2.	Wieser M, Sauerland S, Arnold D, Schmiegel W and Reinacher-Schick A: Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer. 10:3092010. View Article : Google Scholar : PubMed/NCBI
3.	Murata S, Moriya Y, Akasu T, Fujita S and Sugihara K: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer. 83:1086–1093. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Havlik R, Jiao LR, Nicholls J, Jensen SL and Habib NA: Gene therapy for liver metastases. Semin Oncol. 29:202–208. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong Y and Bertino JR: Molecular therapies for colorectal cancer metastatic to the liver. Mol Ther. 5:492–500. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Ruan DT and Warren RS: Liver-directed therapies in colorectal cancer. Semin Oncol. 32:85–94. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Stojdl DF, Lichty B, Knowles S, et al: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 6:821–825. 2000. View Article : Google Scholar : PubMed/NCBI
9.	Balachandran S and Barber GN: Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life. 50:135–138. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Balachandran S, Porosnicu M and Barber GN: Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 75:3474–3479. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Balachandran S and Barber GN: Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell. 5:51–65. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Shinozaki K, Ebert O and Woo SL: Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology. 41:196–203. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Inoue Y, Kashima Y, Aizawa K and Hatakeyama K: A new rat colon cancer cell line metastasizes spontaneously: biologic characteristics and chemotherapeutic response. Jpn J Cancer Res. 82:90–97. 1991. View Article : Google Scholar : PubMed/NCBI
14.	Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A and Woo SL: Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64:3265–3270. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Shinozaki K, Ebert O, Kournioti C, Tai YS and Woo SL: Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther. 9:368–376. 2004. View Article : Google Scholar
16.	Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764. 1994.PubMed/NCBI
17.	Kopecky SA, Willingham MC and Lyles DS: Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol. 75:12169–12181. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Bell JC, Lichty B and Stojdl D: Getting oncolytic virus therapies off the ground. Cancer Cell. 4:7–11. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Giedlin MA, Cook DN and Dubensky TW Jr: Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field’s Virology? Cancer Cell. 4:241–243. 2003.
20.	Lichty BD, Power AT, Stojdl DF and Bell JC: Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med. 10:210–216. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Barber GN: Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17:516–527. 2004. View Article : Google Scholar : PubMed/NCBI
22.	McCormick F: Future prospects for oncolytic therapy. Oncogene. 24:7817–7819. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Everts B and van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 12:141–161. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Shinozaki K, Ebert O and Woo SL: Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus. Int J Cancer. 114:659–664. 2005. View Article : Google Scholar
25.	Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 5:965–976. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Mills BJ and Cooper NR: Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements. J Immunol. 121:1549–1557. 1978.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Related Articles